

Special Issue

Periodontitis: Prevention and Treatment

Message from the Guest Editors

Periodontal disease is associated with biofilm dysbiosis and the overgrowth of culturable and non-culturable pathobionts. In recent years, oral infection has been associated with systemic diseases by disseminating the oral bacteria from the oral microenvironment to other tissues and organs of the body. Currently, much emphasis has been placed on the prevention and treatment of this disease. Currently, topical and systemic antibiotics in periodontal treatment and their resistance are of great interest. However, new approaches are being investigated in preventing and treating periodontal disease and modulation of subgingival biofilm. Likewise, the modulation of periodontal disease by the subgingival biofilm with the systemic treatment of potent anti-inflammatory agents is being studied. This Special Issue welcomes submissions from researchers who have carried out in vitro or in vivo experimental research on different approaches for treating and preventing periodontal disease, including local and systemic antibiotics, probiotics, anti-inflammatories, and antioxidants. The clinical and epidemiological studies investigating these topics are encouraged for this issue.

Guest Editors

Prof. Dr. Gloria Inés Lafaurie

Unidad de Investigación Básica Oral, Universidad El Bosque, Bogotá, Colombia

Dr. Diana Marcela Castillo

Unidad de Investigación Básica Oral, Universidad El Bosque, Bogotá, Colombia

Deadline for manuscript submissions

closed (15 January 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/142542

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)